Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- No Direct Causal Link between Lecanemab and Death in Clinical Trial: Eisai
November 30, 2022
- KM Biologics to File COVID Jab in Japan Spring 2023: Official
November 29, 2022
- Kyowa Kirin Unit, Grunenthal Seal JV Deal for Established Medicines Biz
November 28, 2022
- Mediator Sees Potential for Turnaround in Nichi-Iko’s Restructuring Plan
November 28, 2022
- PeptiDream to Codevelop Lilly's Alzheimer’s Diagnostic Tauvid in Japan
November 25, 2022
- Opdivo Secures Top-Selling Title, Veklury Runner Up in July-September: IQVIA
November 25, 2022
- Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings
November 25, 2022
- AbbVie Japan Launches Maviret for Age 3 and Older
November 25, 2022
- Takeda’s Dengue Vaccine Bags Fast-Track Tag in US
November 25, 2022
- Fujifilm to Build Cell Culture Media Manufacturing Center in US
November 25, 2022
- Chugai to Transfer Bonviva Marketing Rights to Taisho
November 25, 2022
- FunPep’s Functional Peptide Fails in Japan PIII Study for Skin Ulcers
November 25, 2022
- Mitsubishi Tanabe, Sumitomo in Antibiotics Collabs with GARDP
November 25, 2022
- Eisai, Shimadzu Kick Off Blood Biomarker Research ahead of Lecanemab Launch
November 24, 2022
- Pfizer Seeks Breast Cancer Use for Avastin Biosimilar
November 24, 2022
- Japan Oncology Market Estimated to Expand 26% by 2030: Fuji Keizai
November 22, 2022
- Nucala Pediatric Form, Berinert SC, Upgraded Diquas Now Available
November 22, 2022
- Kyowa Kirin/MEI Deliver in Japan PII Trial for B-Cell Non-Hodgkin’s Lymphoma
November 21, 2022
- Alnylam’s Amvuttra Hits Japan Market for hATTR Amyloidosis
November 21, 2022
- Astellas’s Zolbetuximab Hits Goals in PIII Gastric Cancer Trial
November 18, 2022
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…